Ocular Therapeutix Stock Forecast, Price & News

Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions

Is Ocular Therapeutix a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Ocular Therapeutix stock.
View analyst ratings for Ocular Therapeutix or view top-rated stocks.

How has Ocular Therapeutix's stock been impacted by COVID-19?

Ocular Therapeutix's stock was trading at $5.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OCUL shares have increased by 23.6% and is now trading at $6.61.
View which stocks have been most impacted by COVID-19.

Are investors shorting Ocular Therapeutix?

Ocular Therapeutix saw a decline in short interest in the month of October. As of October 29th, there was short interest totaling 4,030,000 shares, a decline of 14.6% from the October 14th total of 4,720,000 shares. Based on an average daily volume of 1,100,000 shares, the short-interest ratio is currently 3.7 days. Approximately 5.3% of the shares of the company are short sold.
View Ocular Therapeutix's Short Interest.

When is Ocular Therapeutix's next earnings date?

Ocular Therapeutix is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Ocular Therapeutix.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) issued its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.03. The biopharmaceutical company had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.13 million. Ocular Therapeutix had a negative net margin of 229.02% and a negative trailing twelve-month return on equity of 22.95%. During the same quarter last year, the company posted ($0.17) EPS.
View Ocular Therapeutix's earnings history.

What price target have analysts set for OCUL?

5 Wall Street analysts have issued twelve-month price objectives for Ocular Therapeutix's shares. Their forecasts range from $14.00 to $30.00. On average, they expect Ocular Therapeutix's share price to reach $24.00 in the next twelve months. This suggests a possible upside of 263.1% from the stock's current price.
View analysts' price targets for Ocular Therapeutix or view top-rated stocks among Wall Street analysts.

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the following people:

• Antony Mattessich, President, Chief Executive Officer & Director (LinkedIn Profile)
• Donald Notman, Chief Financial Officer
• Peter Jarrett, Chief Scientific Officer
• Michael H. Goldstein, Chief Medical Officer & Ophthalmology President
• Rabia Gurses Ozden, Senior Vice President-Clinical Development

Who are some of Ocular Therapeutix's key competitors?

Some companies that are related to Ocular Therapeutix include Taro Pharmaceutical Industries (TARO), Turning Point Therapeutics (TPTX), Reata Pharmaceuticals (RETA), Trillium Therapeutics (TRIL), Global Blood Therapeutics (GBT), Cassava Sciences (SAVA), Ironwood Pharmaceuticals (IRWD), Morphic (MORF), Atai Life Sciences (ATAI), Agios Pharmaceuticals (AGIO), Travere Therapeutics (TVTX), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), Verve Therapeutics (VERV) and Kadmon (KDMN).
View all of OCUL's competitors.

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), (CELG), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.49%), Deltec Asset Management LLC (2.81%), Geode Capital Management LLC (1.71%), Two Sigma Advisers LP (1.40%), Two Sigma Investments LP (1.17%) and Emerald Advisers LLC (1.11%). Company insiders that own Ocular Therapeutix stock include Antony C Mattessich, Opaleye Management Inc, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends for Ocular Therapeutix.

Which institutional investors are selling Ocular Therapeutix stock?

OCUL stock was sold by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Emerald Mutual Fund Advisers Trust, Altshuler Shaham Ltd, Emerald Advisers LLC, UBS Group AG, Goldman Sachs Group Inc., Two Sigma Investments LP, and Two Sigma Advisers LP.
View insider buying and selling activity for Ocular Therapeutix or view top insider-selling stocks.

Which institutional investors are buying Ocular Therapeutix stock?

OCUL stock was purchased by a variety of institutional investors in the last quarter, including Affinity Asset Advisors LLC, Cetera Investment Advisers, Altium Capital Management LP, Millennium Management LLC, Healthcare of Ontario Pension Plan Trust Fund, Morgan Stanley, Kornitzer Capital Management Inc. KS, and Tudor Investment Corp Et Al. Company insiders that have bought Ocular Therapeutix stock in the last two years include Antony C Mattessich, Opaleye Management Inc, and Summer Road Llc.
View insider buying and selling activity for Ocular Therapeutix or or view top insider-buying stocks.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $6.61.

How much money does Ocular Therapeutix make?

Ocular Therapeutix has a market capitalization of $506.39 million and generates $17.40 million in revenue each year. The biopharmaceutical company earns $-155.64 million in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does Ocular Therapeutix have?

Ocular Therapeutix employs 181 workers across the globe.

What is Ocular Therapeutix's official website?

The official website for Ocular Therapeutix is www.ocutx.com.

Where are Ocular Therapeutix's headquarters?

Ocular Therapeutix is headquartered at 15 CROSBY DRIVE, BEDFORD MA, 01730.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at (781) 357-4000, via email at [email protected], or via fax at 781-357-4001.